Data on demographics, clinical parameters, cirrhosis status, HCC imaging, and alpha fetoprotein surveillance were collected to calculate the aMAP score (0–100) based on age, sex, albumin–bilirubin level, and platelet count. This evidence concerns the gene AFP and hepatocellular carcinoma.